IRIDEX Corporation (IRIX)

NASDAQ: IRIX · Real-Time Price · USD
1.590
-0.050 (-3.05%)
Oct 22, 2024, 4:00 PM EDT - Market closed
-3.05%
Market Cap 26.45M
Revenue (ttm) 49.70M
Net Income (ttm) -10.86M
Shares Out 16.64M
EPS (ttm) -0.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 28,758
Open 1.601
Previous Close 1.640
Day's Range 1.530 - 1.635
52-Week Range 1.450 - 3.650
Beta 0.79
Analysts Hold
Price Target 2.00 (+25.79%)
Earnings Date Nov 12, 2024

About IRIX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retino... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Feb 15, 1996
Employees 111
Stock Exchange NASDAQ
Ticker Symbol IRIX
Full Company Profile

Financial Performance

In 2023, IRIDEX's revenue was $51.87 million, a decrease of -8.96% compared to the previous year's $56.97 million. Losses were -$9.57 million, 26.8% more than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for IRIX stock is "Hold" and the 12-month stock price forecast is $2.0.

Price Target
$2.0
(25.79% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Iridex Appoints Patrick Mercer as Chief Executive Officer

MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pro...

19 days ago - GlobeNewsWire

Iridex Frustrates, But Expect A Transaction By Year-End

IRIDEX has faced delays in selling its assets as part of a strategic review initiated a year ago, causing frustration among shareholders. Despite setbacks, the company remains committed to selling all...

2 months ago - Seeking Alpha

IRIDEX Corporation (IRIX) Q2 2024 Earnings Call Transcript

IRIDEX Corporation (NASDAQ:IRIX) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Philip Taylor – Investor Relations David Bruce – Chief Executive Officer Fuad Ahmad – ...

2 months ago - Seeking Alpha

IRIDEX Corporation (IRIX) Q1 2024 Earnings Call Transcript

IRIDEX Corporation (NASDAQ:IRIX) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Company Participants Trip Taylor - Investor Relations David Bruce - Chief Executive Officer Fuad Ahmad - Inte...

5 months ago - Seeking Alpha

Iridex Reports First Quarter 2024 Financial Results

MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and proc...

5 months ago - GlobeNewsWire

Iridex's Strategic Review Process Should Bear Fruit 'Soon'

Iridex Corporation is undergoing a strategic review process to unlock shareholder value. The company is likely to sell its retina business line and potentially parse it out in more than one transactio...

7 months ago - Seeking Alpha

IRIDEX Corporation (IRIX) Q4 2023 Earnings Call Transcript

IRIDEX Corporation (IRIX) Q4 2023 Earnings Call Transcript

7 months ago - Seeking Alpha

Iridex Reports Fourth Quarter and Full Year 2023 Financial Results

MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pr...

7 months ago - GlobeNewsWire

Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024

MOUNTAIN VIEW, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pr...

7 months ago - GlobeNewsWire

Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first ...

9 months ago - GlobeNewsWire

Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma

MOUNTAIN VIEW, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, a global leader in innovative laser-based medical systems for the treatment of eye diseases, proudly announces the US launc...

10 months ago - GlobeNewsWire

Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation

Action Retains Full Patient Access to MicroPulse® Transscleral Laser Treatment Action Retains Full Patient Access to MicroPulse® Transscleral Laser Treatment

10 months ago - GlobeNewsWire

Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation

MOUNTAIN VIEW, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pro...

11 months ago - GlobeNewsWire

Iridex Reports Third Quarter 2023 Financial Results and Business Update

MOUNTAIN VIEW, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pro...

1 year ago - GlobeNewsWire

Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023

The Company also announced plans to present at Stifel Healthcare Conference The Company also announced plans to present at Stifel Healthcare Conference

1 year ago - GlobeNewsWire

Iridex Reimbursement Chaos Presents Buying Opportunity

IRIDEX Corporation's shares rallied over the past several weeks on news it was conducting a strategic review. On November 1, the stock cratered as the company disclosed possible concerns with Medicare...

1 year ago - Seeking Alpha

Iridex to Report Third Quarter Financial Results on November 14, 2023

MOUNTAIN VIEW, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

1 year ago - GlobeNewsWire

Iridex: The Whole Is Less Than The Sum Of The Parts

IRIDEX Corporation is a leading provider of laser-based retinal treatments and is respected in the ophthalmic industry. IRIX stock has experienced a significant decline in value, but the primary reaso...

1 year ago - Seeking Alpha

Iridex Announces Strategic Review to Unlock Shareholder Value

MOUNTAIN VIEW, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) announced today that its Board of Directors is undertaking, in consultation with its financial and legal advi...

1 year ago - GlobeNewsWire

IRIDEX Corporation (IRIX) Q2 2023 Earnings Call Transcript

IRIDEX Corporation (NASDAQ:IRIX) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Philip Taylor - Gilmartin Group David Bruce - President, CEO & Director Fuad Ahmad - ...

1 year ago - Seeking Alpha

Iridex to Report First Quarter Financial Results on May 11, 2023

MOUNTAIN VIEW, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

1 year ago - GlobeNewsWire

IRIDEX Corporation (IRIX) Q4 2022 Earnings Call Transcript

IRIDEX Corporation (NASDAQ:IRIX) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group David Bruce - President and CEO Fua...

1 year ago - Seeking Alpha

Iridex Reports Fourth Quarter and Full Year 2022 Financial Results

Achieves Record Quarterly Glaucoma Probe Sales and 6% Full Year Revenue Growth Achieves Record Quarterly Glaucoma Probe Sales and 6% Full Year Revenue Growth

1 year ago - GlobeNewsWire

Iridex to Present at the 35th Annual Roth Conference

MOUNTAIN VIEW, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

1 year ago - GlobeNewsWire

Iridex Introduces New Research and Showcases Five Events at the AGS Meeting

Five Events at Booth #5

1 year ago - GlobeNewsWire